P. Lothaire (Brussels, Belgium), P. Astoul (Marseille, France)
Pleural fluid, serum β-HCG levels and pleural fluid/serum β-HCG ratio for the discrimination of malignant and benign pleural effusions
F. Ugurman, A. Gozu, G. Onde Ucoluk, B. Akkalyoncu, S. Yordam, B. Samurkasoglu (Ankara, Turkey)
|  |
Telomerase as an immunohistochemical marker for differentiation between reactive and neoplastic pleural lesions?
M. Krismann, P. Thattamparambil, K. M. Mueller (Bochum, Germany)
| |
Telomerase activity as additional diagnostic tool in pleural malignant effusions
E. Kovkarova, T. Stefanovski, D. Dokic, B. Kaeva, O. Jovkovski (Skopje, Macedonia)
| |
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions
J. H. Chung, M. S. Park, Y. S. Kim, S. K. Kim, S. M. Kwak, J. Chang, S. K. Kim (Seoul, Kyunggi-do, South Korea)
| |
Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura
M. Gavrilovski, B. Kaeva, Z. Arsovski (Skopje, Macedonia)
| |
The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE)
B. Kaeva, O. Jovkovski, L. Gligorovski, G. Breskovska, Z. Arsovski (Skopje, Macedonia)
| |
Pleurodesis of malignant pleural effusion with OK432
C. C. Tang, C. T. Yu, H. P. Kuo, H. C. Lin (Taipei, Taiwan)
| |
Video-assisted or slurry pleurodesis? (our experience)
A. M. Arsovski, D. A. Smilevski (Skopje, Macedonia)
| |
Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy
K. P. Zarogoulidis, A. Xafenias, A. Papagianis (Thessaloniki, Greece)
| |
Effecs of systemic inflammation markers for determining success of talc pleurodeisis on patients with malignant pleural effusion
H. Yildirim, M. Metintas, S. Erginel, F. Alatas, I. Ucgun (Eskisehir, Turkey)
| |
Malignant pleural effusion-talc pleurodesis
D. A. Todea, M. V. Cirstoniu, N. N. Ariesanu (Cluj-Napoca, Romania)
| |
Pleural effusion in cases of breast carcinoma
E. Bukurov-Sudjic, D. Mandaric, Z. Uskokovic-Stefanovic, S. Popevic (Belgrade, Yugoslavia)
| |
Prognostic factors in diffuse malignant pleural mesothelioma
G. Ak, M. Metintas, S. Metintas, S. Erginel, F. Alatas, I. Ucgun (Eskisehir, Turkey)
| |
Appropriateness between UICC and IMIG staging systems in management of malignant pleural mesothelioma
G. Ak, M. Metintas, S. Metintas, S. Erginel, I. Ucgun, F. Alatas (Eskisehir, Turkey)
| |
Peritoneal mesothelioma in South West England; histological description of 25 cases
K. A. Gaber, U. O. Igbokwe, M. E. F. Smith, C. R. McGavin (Plymouth, United Kingdom)
| |
Patterns of the infections associated with lung and pleural malignancies
A. Atasever, T. Goksel, S. Soyer, G. Cok, H. Karakus, A. Guzelant, A. Sayiner (Izmir, Turkey)
| |
Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer
J. Wisniewska, W. Z. Tomkowski, P. J. Kuca, M. Szturmowicz, J. Kober (Warsaw, Poland)
| |
Cytotoxic T-lymphocyte status in peripheral blood and malignant pleural effusion in lung cancer
P. Krawczyk, S. Chocholska, M. Wojcik, J. Siwiec, J. Rolinski, J. Milanowski (Lublin, Poland)
| |
Flowcytometric analysis of peripheral blood & pleural fluid lymphocyte subpopulat in tuberculosis pleuritis and malignant pleural effusion
S. D. Mansoori, R. Noorafshar, H. R. Jamaati, H. R. Mohammadi, S. M. Mirsaeidi (Tehran, Iran)
| |